Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted ...

“In addition to TED, we are equally excited by the potential of our FcRn inhibitor portfolio. In Q3 of this year, we anticipate showing proof-of-concept data, including IgG reduction, from our ...

30, 2024. Immunovant has crowned IMVT-1402, a next-generation FcRn inhibitor, as the lead asset going forward given its broad potential across several indications. The company is on track to ...

"In addition to TED, we are equally excited by the potential of our FcRn inhibitor portfolio. In Q3 of this year, we anticipate showing proof-of-concept data, including IgG reduction, from our planned ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.